Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.

Cravit Ophthalmic: Full Drug Profile

Medically reviewed by Dr. Otari Nergadze, Neurosurgeon | Updated: January 2026

Cravit Ophthalmic - General Information

A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. [PubChem]

 

Pharmacology of Cravit Ophthalmic

Cravit Ophthalmic, a fluoroquinolone antiinfective, is the optically active L-isomer of ofloxacin. Cravit Ophthalmic is used to treat bacterial conjunctivitis, sinusitis, chronic bronchitis, community-acquired pneumonia and pneumonia caused by penicillin-resistant strains of Streptococcus pneumoniae, skin and skin structure infections, complicated urinary tract infections and acute pyelonephritis.

 

Cravit Ophthalmic for patients

While taking ofloxacin patient should be advised to:

  • to drink fluids liberally;
  • that mineral supplements, vitamins with iron or minerals, calcium-, aluminum-, or magnesium-based antacids, sucralfate or Videx, (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution should not be taken within the two-hour period before or within the two-hour period after taking ofloxacin;
  • that ofloxacin can be taken without regard to meals;
  • that ofloxacin may cause neurologic adverse effects (e. g., dizziness, lightheadedness) and that patients should know how they react to ofloxacin before they operate an automobile or machinery or engage in activities requiring mental alertness and coordination;
  • to discontinue treatment and inform their physician if they experience pain, inflammation, or rupture of a tendon, and to rest and refrain from exercise until the diagnosis of tendinitis or tendon rupture has been confidently excluded;
  • that ofloxacin may be associated with hypersensitivity reactions, even following the first dose, to discontinue the drug at the first sign of a skin rash, hives or other skin reactions, a rapid heartbeat, difficulty in swallowing or breathing, any swelling suggesting angioedema (e. g., swelling of the lips, tongue, face; tightness of the throat, hoarseness), or any other symptom of an allergic reaction
  • to avoid excessive sunlight or artificial ultraviolet light while receiving ofloxacin and to discontinue therapy if phototoxicity (e. g., skin eruption) occurs;
  • that if they are diabetic and are being treated with insulin or an oral hypoglycemic drug, to discontinue ofloxacin immediately if a hypoglycemic reaction occurs and consult a physician;
  • that convulsions have been reported in patients taking quinolones, including ofloxacin, and to notify their physician before taking this drug if there is a history of this condition.
  •  

    Cravit Ophthalmic Interactions

    Specific drug interaction studies have not been conducted with Levofloxacin. However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.

     

    Cravit Ophthalmic Contraindications

    Levofloxacin solution is contraindicated in patients with a history of hypersensitivity to levofloxacin, to other quinolones, or to any of the components in this medication.

     

    Additional information about Cravit Ophthalmic

    Cravit Ophthalmic Indication

    For the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species, Staphylococus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus (Groups C/F/G), Viridans group streptococci, Acinetobacter lwoffii, Haemophilus influenzae, Serratia marcescens.

    Mechanism Of Action
    Cravit Ophthalmic inhibits bacterial type II topoisomerases, topoisomerase IV and DNA gyrase. Cravit Ophthalmic, like other fluoroquinolones, inhibits the A subunits of DNA gyrase, two subunits encoded by the gyrA gene. This results in strand breakage on a bacterial chromosome, supercoiling, and resealing; DNA replication and transcription is inhibited.
    Drug Interactions
    Aluminium Formation of non-absorbable complexes
    Food Interactions
    Take without regard to meals. Take with water, drink lliberally. Taking this product with orange juice can result in reduced quinolone plasma levels.
    Generic Name
    Levofloxacin
    Synonyms
    L-Ofloxacin
    Drug Category
    Anti-Bacterial Agents; Quinolones; Anti-Infective Agents, Urinary
    Drug Type
    Small Molecule; Approved
    Other Brand Names containing Levofloxacin
    Cravit; Cravit Ophthalmic; Elequine; Floxel; Iquix; Leroxacin; Lesacin; Levaquin; Levokacin; Levox; Levoxacin; Mosardal; Nofaxin; Quixin; Reskuin; Tavanic; Volequin;
    Absorption
    Absorption of ofloxacin after single or multiple doses of 200 to 400 mg is predictable, and the amount of drug absorbed increases proportionately with the dose.
    Toxicity (Overdose)
    Side effects include disorientation, dizziness, drowsiness, hot and cold flashes, nausea, slurring of speech, swelling and numbness in the face
    Protein Binding
    24-38% (to plasma proteins)
    Half Life
    6-8 hours
    Dosage Forms of Cravit Ophthalmic
    Solution Intravenous
    Chemical IUPAC Name
    (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7Hpyrido[1,2,3-de]-1,4 benzoxazine-6-carboxylic acid hemihydrate
    Chemical Formula
    C18H20FN3O4
    Organisms Affected
    Enteric bacteria and other eubacteria